In fact, the risk of hypoglycemia is a barrier to optimal treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM), especially within the context of insulin therapy [5]. The gene discussed is INS; the disease is type 2 diabetes mellitus.